By administering a human anti-OPG therapeutic antibody (Ky3) in murine models, PAH was significantly reduced and reversed by diminishing pulmonary vascular remodeling in small pulmonary arterioles [68]. This evidence concerns the gene TNFRSF11B and pulmonary arterial hypertension.